刘庄教授、陈倩教授及其合作者在Sci. Adv.上发表论文

题目：

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

作者：

JingjingShen^1#, Huiqin Gao^2,3#, Linfu Chen¹, Yutong Jiang¹, Shu Li⁴, Yu Chao¹, Nanhui Liu¹, Yufei Wang¹, Ting Wei¹, Yan Liu^2,3, Jipeng Li^2,3, Muchao Chen¹, Jiafei Zhu¹, Juan Liang⁴, Xiaoyu Zhou⁴, Xiaofeng Zhang⁴*, Ping Gu^2,3*, Qian Chen¹*, Zhuang Liu¹*

单位：

¹Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.

²Department of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, P. R. China.

³Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, P. R. China.

⁴Department of Ophthalmology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, 215123 China.

摘要：

Therapeutic antibodies are extensively used to treat fundus diseases by intravitreal injection, as eyedrop formulation has been rather challenging due to the presence of ocular barriers. Here, an innovative penetrating carrier was developed for antibody delivery in eyedrop formulations. We found that fluorocarbon-modified chitosan (FCS) would self-assemble with proteins to form nanocomplexes, which could effectively pass across the complicated ocular structure to reach the posterior eye segments in both mice and rabbits. In a choroidal melanoma-bearing mouse model, eyedrops containing FCS/anti-PDL1 could induce stronger antitumor immune responses than those triggered by intravenous injection of anti-PDL1. Moreover, in choroidal neovascularization-bearing mouse and rabbit models, FCS/anti-VEGFA eyedrops effectively inhibited vascular proliferation, achieving comparable therapeutic responses to those observed with intravitreal injection of anti-VEGFA. Our work presents an effective delivery carrier to treat fundus diseases using eyedrop of therapeutic proteins, which may enable at-home treatment of many eye diseases with great patient compliance.

影响因子：

14.143

分区情况：

一区

链接：

https://www.science.org/doi/10.1126/sciadv.abq3104